Stellar Pharmaceuticals gets Uracyst patent in Japan

Stellar Pharmaceuticals (OTCQB:SLXCF) has received a patent from the Japan Patent Office for one of its lead products, Uracyst,  covering the treatment of cystitis and other related conditions by instillation into the bladder of a dose comprising of at least 350 mg in a volume of from 10 ml to 100 ml. The patent will [...]

Stellar allowed Uracyst patent in U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to its Uracyst treatment of interstitial cystitis/painful bladder syndrome.  The patent will expire in 2024. The issuance of the patent triggers a milestone payment of $1.3 million (U.S.) from Stellar’s U.S. marketing and distribution [...]

Cowen ups Watson to outperform; Stellar’s Uracyst high in rationale

Cowen & Co. upgraded Watson Pharmaceuticals (NYSE:WPI) to “outperform” from “neutral,” saying it has “significantly underappreciated its brand pipeline” and making an earlier reference to the potential of Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug for painful interstitial cystitis/painful bladder syndrome. Analyst Ken Cacciatore writes that Uracyst, which is sold in Canada by Stellar and in [...]

Stellar signs distributor for Uracyst in Germany and Austria

After tapping into the Portugal market earlier this week, Stellar Pharmaceuticals (OTCBB: SLXCF) signed a license agreement with medac GmbH for the distribution and sale of its Uracyst treatment for interstitial cystitis/painful bladder syndrome in Germany and Austria. “This agreement not only represents an important revenue opportunity for Stellar and medac, but also offers hope [...]

Stellar signs distributor for Uracyst in Portugal

Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug for interstitial cystitis/painful bladder syndrome will be distributed in Portugal by CPH Companhia Portuguesa Higiene, a specialty pharma company with a major focus in urology, the primary target market for Uracyst. “Expanding the global licensing of Uracyst is a major growth driver for Stellar,” CEO, Peter Riehl, said in [...]

Watson has high hopes for Stellar’s Uracyst drug

Watson Pharmaceuticals (NYSE:WPI) CEO, Paul Bisaro, painted a rosy picture of how Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug, which is indicated to treat interstitial cystitis, fills out its urology strategy. According to a presentation at a healthcare conference sponsored by Barclays Capital, Mr. Bisaro said that Watson’s strategy is based on the 10 most common [...]

Stellar outlines strategy at Cowen conference; gets Chinese patent

Upcoming milestones for Stellar Pharmaceuticals (OTCBB:SLXCF) provide for near-and mid-term investment triggers, President and CEO, Peter Riehl, said in a presentation at the SG Cowen healthcare conference in Boston. Stellar, which is only one of three Canadian companies presenting at the Cowen conference, is aggressively expanding its global out-licensing programs for its two lead products [...]

Stellar plugging bladder wall around the world

In 2003, Lana Tenney began chemotherapy following her breast cancer surgery.  And as stressful as that was, things quickly worsened.  She developed a side-effect from chemotherapy called cystitis, a painful bladder condition that oncologists see in 10%-to-15% of cancer patients, who feel an urge to urinate 20-to-30 times a day, whether they can or can’t. [...]

Stellar results from Stellar Pharmaceuticals

London-Ont.-based Stellar Pharmaceuticals (OTCBB:SLXCF) reported strong third quarter financial results today. The company’s revenues grew by 71.9%, driven by 7.9% and 303.1% growth in Canadian and International sales, respectively.   Net income grew by 42.9%.   This was the fourth consecutive quarter Stellar has generated a profit. Stellar has developed and is marketing direct in Canada and in [...]

Stellar gets South Korea distributor for Uracyst

Stellar Pharmaceuticals (OTCBB:SLXCF) has signed a licensing agreement for the distribution and sale of one of its lead products, Uracyst, to treat interstitial cystitis/painful bladder syndrome in South Korea with Jeilmedix Pharmaceutical. Peter Riehl, Stellar’s CEO, said in a statement that the accord is in line with the company’s strategy of selling direct in Canada [...]

Next Page »